Cargando…

Long−Term Follow−Up of a Pseudohypoparathyroidism Type 1A Patient with Missense Mutation (Pro115Ser) in Exon 5

Pseudohypoparathyroidism (PHP) refers to end−organ resistance that primarily impairs the renal actions of parathyroid hormone (PTH). The patients with PHP type Ia (PHP−Ia), one of the 4 types of PHP, show resistance to other peptide hormones as well as clinical features of Albright hereditary osteod...

Descripción completa

Detalles Bibliográficos
Autores principales: Erdeve, Şenay Savaş, Berberoğlu, Merih, Şıklar, Zeynep, Evliyaoğlu, Olcay, Hiort, Olaf, Öcal, Gönül
Formato: Texto
Lenguaje:English
Publicado: Galenos Publishing 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005667/
https://www.ncbi.nlm.nih.gov/pubmed/21274345
http://dx.doi.org/10.4274/jcrpe.v2i2.85
_version_ 1782194118716293120
author Erdeve, Şenay Savaş
Berberoğlu, Merih
Şıklar, Zeynep
Evliyaoğlu, Olcay
Hiort, Olaf
Öcal, Gönül
author_facet Erdeve, Şenay Savaş
Berberoğlu, Merih
Şıklar, Zeynep
Evliyaoğlu, Olcay
Hiort, Olaf
Öcal, Gönül
author_sort Erdeve, Şenay Savaş
collection PubMed
description Pseudohypoparathyroidism (PHP) refers to end−organ resistance that primarily impairs the renal actions of parathyroid hormone (PTH). The patients with PHP type Ia (PHP−Ia), one of the 4 types of PHP, show resistance to other peptide hormones as well as clinical features of Albright hereditary osteodystrophy (AHO), a constellation of short stature, obesity, brachydactyly, ectopic ossifications, and/or mental retardation. Here we report clinical follow−up for a long−term period in a PHP−Ia case who had a missense mutation leading to the substitution of proline by serine (Prol115Ser) in exon 5 which has been reported previously in only two patients. An 11−year−old boy applied for hand spasm to our hospital. On physical examination, he had short stature, round−shaped face and brachydactly. Laboratory evaluation revealed PTH and TSH resistance. Molecular genetic analysis of the GNAS gene revealed a P115S substitution. The patient was followed up for 13 years. Normocalcaemia was achieved with reduced doses of calcitriol (0.25 μg/day) and calcium supplements (40 mg/kg/day). Daily requirement for levothyroxine supplementation was still high (2.3 μg/kg) to achieve euthyroidism. His pubertal development was Tanner stage V and he has no gonadotropin resistance. To our knowledge, this is the first report concerning long−term follow−up of this rare mutation. We believe that despite the genetic heterogeneity of AHO, phenotype/genotype correlations of this kind of rare mutations may help to understand progress of the disease. Conflict of interest:None declared.
format Text
id pubmed-3005667
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-30056672011-01-27 Long−Term Follow−Up of a Pseudohypoparathyroidism Type 1A Patient with Missense Mutation (Pro115Ser) in Exon 5 Erdeve, Şenay Savaş Berberoğlu, Merih Şıklar, Zeynep Evliyaoğlu, Olcay Hiort, Olaf Öcal, Gönül J Clin Res Pediatr Endocrinol Case Reports Pseudohypoparathyroidism (PHP) refers to end−organ resistance that primarily impairs the renal actions of parathyroid hormone (PTH). The patients with PHP type Ia (PHP−Ia), one of the 4 types of PHP, show resistance to other peptide hormones as well as clinical features of Albright hereditary osteodystrophy (AHO), a constellation of short stature, obesity, brachydactyly, ectopic ossifications, and/or mental retardation. Here we report clinical follow−up for a long−term period in a PHP−Ia case who had a missense mutation leading to the substitution of proline by serine (Prol115Ser) in exon 5 which has been reported previously in only two patients. An 11−year−old boy applied for hand spasm to our hospital. On physical examination, he had short stature, round−shaped face and brachydactly. Laboratory evaluation revealed PTH and TSH resistance. Molecular genetic analysis of the GNAS gene revealed a P115S substitution. The patient was followed up for 13 years. Normocalcaemia was achieved with reduced doses of calcitriol (0.25 μg/day) and calcium supplements (40 mg/kg/day). Daily requirement for levothyroxine supplementation was still high (2.3 μg/kg) to achieve euthyroidism. His pubertal development was Tanner stage V and he has no gonadotropin resistance. To our knowledge, this is the first report concerning long−term follow−up of this rare mutation. We believe that despite the genetic heterogeneity of AHO, phenotype/genotype correlations of this kind of rare mutations may help to understand progress of the disease. Conflict of interest:None declared. Galenos Publishing 2010-06 2010-05-07 /pmc/articles/PMC3005667/ /pubmed/21274345 http://dx.doi.org/10.4274/jcrpe.v2i2.85 Text en © Journal of Clinical Research in Pediatric Endocrinology, Published by Galenos Publishing. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Erdeve, Şenay Savaş
Berberoğlu, Merih
Şıklar, Zeynep
Evliyaoğlu, Olcay
Hiort, Olaf
Öcal, Gönül
Long−Term Follow−Up of a Pseudohypoparathyroidism Type 1A Patient with Missense Mutation (Pro115Ser) in Exon 5
title Long−Term Follow−Up of a Pseudohypoparathyroidism Type 1A Patient with Missense Mutation (Pro115Ser) in Exon 5
title_full Long−Term Follow−Up of a Pseudohypoparathyroidism Type 1A Patient with Missense Mutation (Pro115Ser) in Exon 5
title_fullStr Long−Term Follow−Up of a Pseudohypoparathyroidism Type 1A Patient with Missense Mutation (Pro115Ser) in Exon 5
title_full_unstemmed Long−Term Follow−Up of a Pseudohypoparathyroidism Type 1A Patient with Missense Mutation (Pro115Ser) in Exon 5
title_short Long−Term Follow−Up of a Pseudohypoparathyroidism Type 1A Patient with Missense Mutation (Pro115Ser) in Exon 5
title_sort long−term follow−up of a pseudohypoparathyroidism type 1a patient with missense mutation (pro115ser) in exon 5
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005667/
https://www.ncbi.nlm.nih.gov/pubmed/21274345
http://dx.doi.org/10.4274/jcrpe.v2i2.85
work_keys_str_mv AT erdevesenaysavas longtermfollowupofapseudohypoparathyroidismtype1apatientwithmissensemutationpro115serinexon5
AT berberoglumerih longtermfollowupofapseudohypoparathyroidismtype1apatientwithmissensemutationpro115serinexon5
AT sıklarzeynep longtermfollowupofapseudohypoparathyroidismtype1apatientwithmissensemutationpro115serinexon5
AT evliyaogluolcay longtermfollowupofapseudohypoparathyroidismtype1apatientwithmissensemutationpro115serinexon5
AT hiortolaf longtermfollowupofapseudohypoparathyroidismtype1apatientwithmissensemutationpro115serinexon5
AT ocalgonul longtermfollowupofapseudohypoparathyroidismtype1apatientwithmissensemutationpro115serinexon5